Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus DISPERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus DISPERMOX.
AUGMENTIN '250' vs DISPERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic